Logo

Biomax Informatics Raises EUR2.25M in VC Funding

Oct 13, 2004

This article has been updated from an  earlier version to reflect that Biomax Solutions is independent of Biomax Informatics.

 

NEW YORK, Oct. 13 (GenomeWeb News) - Biomax Informatics has raised €2.25 million ($2.75 million) in venture capital funding, the Munich-based company said yesterday.

 

Investors included BayBG Bayerische Beteiligungsgesellschaft, Ecos Venture Capital Beteiligungs AG, and S-UBG Bayern Gesellschaft  f r  Unternehmensbeteiligungen. There was no lead investor, according to Biomax CFO Hein Osenberg.

 

Biomax plans to use the funding to develop new products and to expand its business in the US. Osenberg told GenomeWeb News that the company wants to expand its marketing and sales activies in the US, working together with its independent US partner, Biomax Solutions, which is based in Falmouth, Mass.

Breaking News
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.